Les Miller, CRT Presentation
Click image to see full size

Minimally Invasive Circulatory Assist Devices

Product Summary

Second Heart is developing a minimally invasive circulatory support platform based on proprietary aortic stent pump technology. The platform will be deployed using low profile catheter-based techniques and will provide either temporary or chronic circulatory support, depending on the specific needs of the patient. Second Heart’s initial product will be a catheter-based temporary assist pump to treat patients with acute decompensated heart failure and to provide circulatory support to those undergoing high-risk percutaneous coronary intervention (PCI). The second application will be a wirelessly powered circulatory assist pump that will provide chronic circulatory support for heart failure patients.

Key features of Second Heart’s platform include:

  • A higher flow (with lower RPMs) rate than other systems at over 7 liters per minute.
  • Pump placement just above the renal arteries will provide additional benefit for heart failure patients with kidney dysfunction.
  • A choice of pulsatile or continuous flow to optimize hemodynamics and lessen the risk of thrombosis.
  • The only system to use the full inner diameter of the aorta to increase pump stability and reduce pump migration.
  • Lower risk of mechanical failure due to simple impeller deployment mechanism, improved bearings, and liquid cooled drive shaft.

Latest News

Second Heart Assist Flow Model Demo Pulsaltility

Only system known that has the delicate balance right of firmly fixating to the aortic wall to avoid migration and re-positioning risks and at the same time being sufficiently compliant not to interfere with aortic wall motion and not to damage the aortic wall. You...

Howard Leonhardt and Alex Richardson of Second Heart Assist discuss regenerating hearts and novel medical devices

During their recent visit to Victoria BC for lab testing services, Second Heart Assist Chairman and CEO, Howard Leonhardt (HL), and VP of Engineering & Product Development, Alex Richardson (AR), spoke with ViVitro Lab and Interim General Manager, Rob Fraser (RF),...

Leonhardt’s Launchpads Accelerator Announces Demo Days and Showcases September in San Francisco and Palo Alto for Organ Regeneration and Recovery Focused Startups

Leonhardt's Launchpads www.leonhardtventures.com an innovation and startup accelerator focused exclusively on organ and tissue regeneration and recovery technologies announced today Demo Days and Innovation Showcases to take place in San Francisco September 26th and...

Leonhardt’s Launchpads Partners With DeviceLab For Prototype Building

Press Release – LOS ANGELES, CALIFORNIA – 05/23/2018 (PRESS RELEASE JET) – Leonhardt’s Lauchhpads an innovation and startup accelerator www.leonhardtventures.com focused on organ regeneration and recovery technologies based in Los Angeles and Salt Lake City...


Alex Richardson
VP Engineering & Product Development

Asli Gozoren
Chief Advisor, Investor Relations

Brittany Brown
Board Director

Dinesh Patel
Board Director

Howard Leonhardt
Chairman, CEO

Jeff Donofrio

Ken Evans
VP Corporate Development, Board Director

Kurt Kruger
Chief Advisor Biomedical Engineering & Finance

Larry Stevens
Chief Advisor Regulatory Affairs

Leslie Miller
Chief Medical Officer

Mark Cunningham
Chief Advisor CardioThoracic Surgery

Nic Chronos
Chief Advisor Research

Todd Seiger
Chief Advisor Reimbursement

Tom Newman
Associate Director Physician Relations

CAUTION Disclaimer and Warning: Products described on this web site are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. Investigational use only in countries where investigation is permitted by law and proper filings have been made and appropriate regulatory clearances have been granted. Any use of the product(s) must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent procedures followed. For other countries product is only available for laboratory investigation by credentialed institutions and investigators with proper clearances with a research agreement in place with a study sponsor. NOT AVAILABLE FOR SALE.